Abbott's profit jumps on sales growth - Reuters

Reuters) — Abbott Laboratories said Wednesday that fourth-quarter earnings jumped 28 percent on demand for its prescription drugs, nutritional products and medical devices, including its new Xience stent used to prop open coronary arteries.

The strong performance, based on double-digit sales growth for its major business units, stood in marked contrast to Johnson & Johnson, its diversified health care rival, which on Tuesday attributed anemic quarterly results partly to the economic downturn.

Read More Here ...
(Second "read more" link no longer functional)